A number of research firms have changed their ratings and price targets for Eli Lilly and Company (NYSE: LLY):
- 11/17/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $1,600.00 price target on the stock.
- 11/16/2026 – Eli Lilly and Company had its price target raised by Barclays from $1,400.00 to $1,550.00. They now have an “overweight” rating on the stock.
- 11/13/2026 – Eli Lilly and Company was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
- 11/12/2026 – Eli Lilly and Company was downgraded by China Merchants Securities from “buy” to “hold”.
- 11/9/2026 – Eli Lilly and Company had its price target raised by Jefferies Financial Group from $1,610.00 to $1,700.00. They now have a “buy” rating on the stock.
- 11/2/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,440.00 to $1,600.00. They now have an “overweight” rating on the stock.
- 10/31/2026 – Eli Lilly and Company was upgraded by Wall Street Zen from “hold” to “buy”.
- 10/30/2026 – Eli Lilly and Company was downgraded by Weiss Ratings from “buy (b+)” to “buy (b)”.
- 10/30/2026 – Eli Lilly and Company had its price target raised by Argus from $1,300.00 to $1,550.00. They now have a “buy” rating on the stock.
- 10/30/2026 – Eli Lilly and Company had its price target raised by UBS Group from $1,425.00 to $1,625.00. They now have a “buy” rating on the stock.
- 10/30/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $1,650.00 price target on the stock.
- 10/30/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by Bank of America. They now have a $1,497.00 price target on the stock.
- 10/30/2026 – Eli Lilly and Company had its price target raised by Wells Fargo & Company from $1,330.00 to $1,500.00. They now have an “overweight” rating on the stock.
- 10/30/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by Truist Financial. They now have a $1,612.00 price target on the stock, up from $1,376.00.
- 10/30/2026 – Eli Lilly and Company had its price target raised by JPMorgan Chase & Co. from $1,500.00 to $1,650.00. They now have an “overweight” rating on the stock.
- 10/30/2026 – Eli Lilly and Company had its price target raised by Citigroup from $1,600.00 to $1,650.00. They now have a “buy” rating on the stock.
- 10/30/2026 – Eli Lilly and Company had its price target raised by Scotiabank from $1,300.00 to $1,605.00. They now have a “sector outperform” rating on the stock.
- 10/30/2026 – Eli Lilly and Company had its price target raised by Morgan Stanley from $1,430.00 to $1,596.00. They now have an “overweight” rating on the stock.
- 10/30/2026 – Eli Lilly and Company had its price target raised by Royal Bank Of Canada from $1,500.00 to $1,600.00. They now have an “outperform” rating on the stock.
- 10/26/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Sanford C. Bernstein. They now have a $1,450.00 price target on the stock.
- 10/21/2026 – Eli Lilly and Company had its price target raised by Leerink Partners from $1,309.00 to $1,316.00. They now have an “outperform” rating on the stock.
- 10/20/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by The Goldman Sachs Group. They now have a $1,413.00 price target on the stock.
- 10/17/2026 – Eli Lilly and Company was downgraded by Wall Street Zen from “buy” to “hold”.
- 10/15/2026 – Eli Lilly and Company was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
- 10/12/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $1,500.00 price target on the stock.
- 10/8/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,410.00 to $1,440.00. They now have an “overweight” rating on the stock.
- 10/7/2026 – Eli Lilly and Company had its price target raised by Morgan Stanley from $1,419.00 to $1,430.00. They now have an “overweight” rating on the stock.
- 10/1/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets.
- 9/28/2026 – Eli Lilly and Company had its price target raised by JPMorgan Chase & Co. from $1,400.00 to $1,500.00. They now have an “overweight” rating on the stock.
- 9/22/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by TD Cowen. They now have a $1,250.00 price target on the stock.
Eli Lilly and Company Stock Down 2.2%
Shares of Eli Lilly and Company stock opened at $1,352.18 on Friday. The stock has a 50-day moving average price of $1,263.45 and a 200 day moving average price of $1,117.53. The company has a market cap of $1.27 trillion, a P/E ratio of 43.89, a P/E/G ratio of 1.65 and a beta of 0.40. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,475.25.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same period last year, the company posted $7.02 EPS. The business’s quarterly revenue was up 38.6% compared to the same quarter last year. As a group, analysts expect that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.
Eli Lilly and Company Announces Dividend
Insider Activity at Eli Lilly and Company
In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Read More
- Five stocks we like better than Eli Lilly and Company
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
